Get the Daily Brief
Latest Biotech News
United Therapeutics’ Inhaled Tyvaso Shows Surprising Phase 3 Win for Idiopathic Pulmonary Fibrosis
United Therapeutics reported unexpected positive results from a Phase 3 trial of nebulized Tyvaso (treprostinil) for idiopathic pulmonary fibrosis, a condition known for its limited treatment...
Advancements in AI for Precision Medicine and Biopharma Automation
Innovations continue to surge at the interface of artificial intelligence and biotech, with notable developments in AI-enhanced virtual cell models, antibody discovery platforms, and laboratory...
New Cancer Diagnostic and Imaging Technologies Gain Regulatory Clearance
Multiple diagnostic and imaging innovations advanced regulatory milestones augmenting cancer care. Geneseeq Technology received FDA 510(k) clearance for its GeneseeqPrime NGS Tumor Profiling Assay...
Amgen’s $600 Million Investment Elevates California Headquarters with New Innovation Center
Amgen announced plans to invest over $600 million into a state-of-the-art Center for Science and Innovation at its Thousand Oaks, California headquarters. Designed to integrate multidisciplinary...
Novartis Deepens Parkinson’s RNAi Bet with $200M Arrowhead License
Novartis has committed an upfront $200 million to Arrowhead Pharmaceuticals for exclusive rights to develop ARO-SNCA, a preclinical RNA interference therapy targeting alpha-synuclein, implicated...
Mercy BioAnalytics Secures $59M to Launch Ovarian Cancer Test
Supported by a $59 million Series B funding round, Mercy BioAnalytics intends to commercialize its blood-based ovarian cancer test in early 2026. Leveraging its Halo platform, which detects...
Wave Life Sciences Shows Proof of Concept for RNA Editing in AATD
Wave Life Sciences released updated clinical data from its phase Ib/IIa study for WVE-006, an RNA editing therapy aimed at alpha-1 antitrypsin deficiency (AATD). The data demonstrated sustained...
Amgen Commits $600M to New U.S. Science and Innovation Center
Amgen announced a $600 million investment to build a state-of-the-art center for science and innovation at its global headquarters in Thousand Oaks, California. The new center aims to integrate...
Treeline Biosciences Raises Over $1.1B, Advances Multiple Cancer Drugs
Treeline Biosciences surfaced from stealth with disclosures of $200 million raised in a series A extension and announced three oncology drug candidates in clinical testing. The Massachusetts-based...
Precision Diagnostics: NeoGenomics Wins Patent Battle, Fuels MRD Commercialization
NeoGenomics secured a summary judgement invalidating key patents asserted by rival Natera, lifting an injunction that had halted commercialization of its Radar minimal residual disease (MRD)...
FDA Approvals and Regulatory Updates Highlight Momentum in Biotech Pipeline
August 2025 saw the FDA approve five new molecular entities, continuing strong regulatory activity in the biotech sector. Notably, Boehringer Ingelheim's Zongertinib received FDA approval in...
Microsoft-Backed Fiber Optics Innovation Promises Faster, Longer-Range Internet
Researchers from the University of Southampton and Lumenisity have developed hollow optical fibers with intricate glass microstructures that confine light more efficiently, enabling faster data...
Quantum Advances: DNA-Based Neural Networks and Long-Range Entanglement
Pioneering studies at Caltech and other institutions have demonstrated DNA molecules programmed to function as supervised neural networks, representing a novel direction for molecular computing...
Treeline Biosciences Unveils First Clinical Candidates With Over $1 Billion Funding
Treeline Biosciences, a Massachusetts-based biotech startup, has revealed details of its pipeline including three cancer drug candidates entering clinical testing. The company has raised over $1.1...
FDA Accepts First Biosimilar Without Clinical Efficacy Studies, Pioneered by Professor Niazi
Professor Sarfaraz K. Niazi has secured a historic regulatory milestone with the FDA’s acceptance of a biosimilar application without requiring clinical efficacy studies (CESs). This breakthrough,...
Positive Phase 3 Results Boost Ionis’ Olezarsen as Leading Therapy for Severe Hypertriglyceridemia
Ionis Pharmaceuticals reported positive topline outcomes from two pivotal Phase 3 studies (CORE and CORE2) of olezarsen, targeting severe hypertriglyceridemia (sHTG). The therapy achieved up to...
Novartis and Arrowhead Extend Collaboration With $200M Upfront for Parkinson’s RNAi Therapy
Novartis has entered a significant licensing and collaboration agreement with Arrowhead Pharmaceuticals, investing $200 million upfront for rights to ARO-SNCA, a preclinical siRNA therapy...
Mercy BioAnalytics Secures $59M Series B to Launch Ovarian Cancer Blood Test in 2026
Mercy BioAnalytics, a cancer early detection firm based in Waltham, Massachusetts, closed a $59 million Series B to fund commercialization of its blood-based ovarian cancer screening test slated...
Comprehensive Brain-Wide Neural Activity Maps Reveal Distributed Decision-Making Networks
The International Brain Laboratory published the first full brain-wide single-neuron activity map during decision-making behavior in mice, recording over 500,000 neurons across 279 brain areas and...
Amgen Commits $600 Million to Advanced Science and Innovation Center in California
Amgen announced plans to invest over $600 million to construct a new state-of-the-art center for science and innovation at its global headquarters in Thousand Oaks, California. The facility will...